Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and ...
Introduction Implementation of low-intensity, evidence-based psychological interventions can help meet the mental health and ...
Background Intensive blood pressure (BP) control <130/80 mm Hg could bring additional benefits for cardiovascular disease ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent ...
Breathlessness intervention services (BIS), which coach patients to self-manage breathlessness using non-pharmacological ...
Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Introduction Cognitive impairment is a common consequence after stroke. Intermittent theta burst stimulation (iTBS) has emerged as a promising cognitive therapy. However, traditional iTBS typically ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...
Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...
A healthy Nordic diet, high in dietary fibre from whole grains, fruits and vegetables but with a small percentage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback